Albert Bourla said. The company is looking to data on the vaccine’s performance from health providers and other sources to give a clearer picture of effectiveness, Bourla said Wednesday in an interview on Bloomberg Television’s “Balance of Power With David Westin." “What I really think will be the final verdict will be the real-world data," he said. “We are expecting to see those toward the end of the year." On Wednesday, Pfizer and partner BioNTech SE released results of laboratory experiments on the highly transmissible variant’s evasion of vaccines that were obtained with a construct called a pseudovirus, Bourla said.